{"id":90119,"date":"2023-03-27T12:00:00","date_gmt":"2023-03-27T10:00:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=90119"},"modified":"2023-03-27T11:50:49","modified_gmt":"2023-03-27T09:50:49","slug":"mbiomics-series-a","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/","title":{"rendered":"Series A: 13 million euros for Mbiomics"},"content":{"rendered":"
\n

Mbiomics focuses on developing the first generation of effective live bacterial therapeutics. The company uses its proprietary profiling platform and computational technologies to generate high-resolution precision data for microbiota modulation. The technology is intended to enable a better understanding of the interactions between the gut microbiome and the host, allowing Mbiomics to develop microbial consortia that can be delivered to patients as precision therapies. The Munich-based company Biotech<\/a>The company aims to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases. <\/p>\n\n\n\n

\u201cHarnessing the power of the microbiome to treat diseases\u201d<\/h2>\n\n\n\n

Markus Rinecker, <\/strong>Co-founder and CMO of Mbiomics<\/a>, says:<\/p>\n\n\n\n

"The microbiome offers a rich source of new therapeutic opportunities that have not yet been fully explored. Our goal is to harness the power of the microbiome to treat diseases that are difficult to treat with conventional approaches. Our outstanding R&D team has delivered a technological proof of concept for our analysis platform in record time. With this technology, Mbiomics is uniquely positioned to understand microbiome modulation and develop effective therapies."<\/p><\/blockquote>\n\n\n\n

Laura Figulla,<\/strong> Co-founder and CEO of Mbiomics, adds:<\/p>\n\n\n\n

"We are delighted to have the support of such a distinguished group of investors who share our vision of harnessing the power of the gut microbiome to develop targeted therapies. This financing allows us to build our platform, accelerate the selection of our first lead product candidates, and intensify research activities toward clinical validation."<\/p><\/blockquote>\n\n\n\n

\u201cGreat potential\u201d<\/h2>\n\n\n\n

\u201cThe influence of the microbiome on diseases is currently being widely researched,\u201d<\/p><\/blockquote>\n\n\n\n

so Monika Steger, <\/strong>Managing Director of Bayern Kapital. <\/p>\n\n\n\n

"Mbiomics shows great potential in the development of microbiome-based therapeutics for supportive intervention in various diseases and can thus advance research a decisive step forward. We look forward to pursuing this path together with the company and an experienced and financially strong investor consortium."<\/p><\/blockquote>\n\n\n\n

And Jan Engels,<\/strong> Investment Manager at High-Tech Gr\u00fcnderfonds, adds:<\/p>\n\n\n\n

"In the development of live bacterial products, microbiome profiling remains one of the most challenging aspects. Mbiomics has developed a novel high-performance profiling platform that addresses the key bottlenecks in the development of microbiome-based therapeutic approaches using novel bacterial consortia. We are pleased to invest in an excellent team and innovative technology together with strong co-investors," <\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"

The Munich-based biotech company Mbiomics, which develops microbiome-based therapeutics, has secured a \u20ac13 million Series A. In addition to Bayern Kapital, MIG Capital participated as lead investor, as did High-Tech Gr\u00fcnderfonds and other private investors in the first closing of the round.<\/p>","protected":false},"author":24,"featured_media":47148,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1],"tags":[371,52,4832],"acf":[],"yoast_head":"\nSeries-A: 13 Millionen Euro f\u00fcr Mbiomics - Munich Startup<\/title>\n<meta name=\"description\" content=\"Das M\u00fcnchener Unternehmen Mbiomics, das Mikrobiom-basierte Therapeutika entwickelt, sichert sich eine Series-A \u00fcber 13 Millionen Euro.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Series-A: 13 Millionen Euro f\u00fcr Mbiomics - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Das M\u00fcnchener Unternehmen Mbiomics, das Mikrobiom-basierte Therapeutika entwickelt, sichert sich eine Series-A \u00fcber 13 Millionen Euro.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T10:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Regina Bruckschl\u00f6gl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Regina Bruckschl\u00f6gl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/\",\"name\":\"Series-A: 13 Millionen Euro f\u00fcr Mbiomics - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg\",\"datePublished\":\"2023-03-27T10:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f\"},\"description\":\"Das M\u00fcnchener Unternehmen Mbiomics, das Mikrobiom-basierte Therapeutika entwickelt, sichert sich eine Series-A \u00fcber 13 Millionen Euro.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg\",\"width\":1280,\"height\":852,\"caption\":\"Invest Risikokapital Investitionsrekord Fintech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Series-A: 13 Millionen Euro f\u00fcr Mbiomics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f\",\"name\":\"Regina Bruckschl\u00f6gl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g\",\"caption\":\"Regina Bruckschl\u00f6gl\"},\"description\":\"Nach eigenen Startup-Erfahrungen blickt sie als Redakteurin von Munich Startup nun aus einer anderen Perspektive auf die M\u00fcnchner Startup-Szene \u2013 und entdeckt dabei jeden Tag, wie vielf\u00e4ltig das M\u00fcnchner \u00d6kosystem ist. Startup Stories, die erz\u00e4hlt werden wollen!\",\"sameAs\":[\"https:\/\/cms.munich-startup.net\"],\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/regina\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"852\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Series A: 13 million euros for Mbiomics - Munich Startup","description":"The Munich-based company Mbiomics, which develops microbiome-based therapeutics, secures a Series A of 13 million euros.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/","og_locale":"en_US","og_type":"article","og_title":"Series-A: 13 Millionen Euro f\u00fcr Mbiomics - Munich Startup","og_description":"Das M\u00fcnchener Unternehmen Mbiomics, das Mikrobiom-basierte Therapeutika entwickelt, sichert sich eine Series-A \u00fcber 13 Millionen Euro.","og_url":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2023-03-27T10:00:00+00:00","author":"Regina Bruckschl\u00f6gl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Regina Bruckschl\u00f6gl","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/","url":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/","name":"Series A: 13 million euros for Mbiomics - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg","datePublished":"2023-03-27T10:00:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f"},"description":"The Munich-based company Mbiomics, which develops microbiome-based therapeutics, secures a Series A of 13 million euros.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg","width":1280,"height":852,"caption":"Invest Risikokapital Investitionsrekord Fintech"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/en\/90119\/mbiomics-series-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Series-A: 13 Millionen Euro f\u00fcr Mbiomics"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f","name":"Regina Bruckschl\u00f6gl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g","caption":"Regina Bruckschl\u00f6gl"},"description":"After her own startup experiences, she now looks at the Munich startup scene from a different perspective as an editor at Munich Startup \u2013 and discovers every day how diverse the Munich ecosystem is. Startup stories that beg to be told!","sameAs":["https:\/\/cms.munich-startup.net"],"url":"https:\/\/cms.munich-startup.net\/en\/author\/regina\/"}]},"og_image":[{"width":1280,"height":852,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/bank-note-209104_1280.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1679910997:26","_edit_last":"26","_yoast_wpseo_focuskw":"Mbiomics","_yoast_wpseo_metadesc":"Das M\u00fcnchener Unternehmen Mbiomics, das Mikrobiom-basierte Therapeutika entwickelt, sichert sich eine Series-A \u00fcber 13 Millionen Euro.","_yoast_wpseo_linkdex":"76","_thumbnail_id":"47148","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"30","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"0","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/90119"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=90119"}],"version-history":[{"count":2,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/90119\/revisions"}],"predecessor-version":[{"id":90123,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/90119\/revisions\/90123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/47148"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=90119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=90119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=90119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}